Propel Bio Management
IRD icon

Propel Bio Management’s Opus Genetics IRD Stock Holding History

Propel Bio Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.31M Buy
+270,036
New +$1.12M 0.69% 27

Other funds holding IRD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
AIC
AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Propel Bio Management's IRD Position: Q3 2026 in Review

Propel Bio Management opened a new position in Opus Genetics (IRD) in Q3 2026: 270,036 shares worth $1.31M. The stake represents 0.69% of the portfolio and ranks #27 among its holdings.

74 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Propel Bio Management held 270,036 shares of Opus Genetics worth $1.31M as of Q3 2026.
  • Opus Genetics was a new Propel Bio Management position in Q3 2026.
  • Opus Genetics made up 0.69% of Propel Bio Management's portfolio in Q3 2026, its #27 holding.
  • 74 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Propel Bio Management's 13F filing for Q3 2026, filed 13 Nov 2026.